(Nemolizumab)Biosimilar Reference Antibody-GS40468

货号：GS40468

Nemolizumab is a humanized monoclonal antibody that targets the interleukin‑31 receptor A (IL‑31RA), a key component of the receptor for interleukin‑31 (IL‑31). By binding to IL‑31RA, it blocks the interaction between IL‑31 and its receptor, thereby inhibiting downstream JAK/STAT signaling that drives pruritus (itch) and inflammation. IL‑31 is a major pruritogenic cytokine in atopic dermatitis (eczema). Nemolizumab is approved in Japan for the treatment of pruritus associated with atopic dermatitis and is under regulatory review in other regions for the same indication. It is administered via subcutaneous injection and has shown significant efficacy in reducing itch and improving skin lesions.